The U.S. Food and Drug Administration removed the clinical hold that had been placed on Intellia Therapeutics’ MAGNITUDE Phase 3 trial for nexiguran ziclumeran (nex‑z) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) on March 2, 2026. The hold, imposed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased bilirubin, was lifted after the company and the FDA agreed on enhanced monitoring and risk‑mitigation measures.
The lift allows Intellia to resume enrollment of the 1,200‑patient MAGNITUDE study, a pivotal trial that could lead to the first one‑time gene‑editing therapy for ATTR‑CM. By removing the regulatory overhang, the company can continue collecting safety and efficacy data, maintain its development timeline, and move toward a potential regulatory submission.
Intellia’s Q4 2025 earnings, released on February 26, 2026, beat expectations with revenue of $23.02 million—an 90.6% surprise over the consensus estimate of $12.08 million—and an EPS loss of $0.83, a $0.16 beat over the $0.97 estimate. The revenue surge was driven by strong collaboration revenue, which rose from $12.9 million in Q4 2024 to $23 million in Q4 2025, reflecting robust demand from Regeneron and other partners. The EPS beat was largely attributable to disciplined cost control and the absence of one‑time charges that had impacted prior periods.
The announcement was well received by investors, with analysts upgrading Intellia to Outperform. The market reaction was driven by the removal of the clinical hold, which eliminated a significant regulatory risk, and by the company’s strong Q4 earnings, which demonstrated effective execution and a solid cash position of $605.1 million as of December 31, 2025.
John Leonard, Intellia’s President and CEO, said, “We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate nex‑z in a broad ATTR‑CM population.”
The MAGNITUDE trial is part of Intellia’s broader ATTR program, which also includes the MAGNITUDE‑2 Phase 3 study for hereditary ATTR with polyneuropathy. The company’s pipeline extends to a Phase 3 trial for hereditary angioedema (HAELO) expected to report top‑line data in mid‑2026, with a U.S. launch targeted for the first half of 2027. The company’s focus on gene‑editing and gene‑silencing modalities positions it in a growing market that currently includes TTR stabilizers and silencers.
In summary, the FDA’s decision to lift the clinical hold removes a key regulatory hurdle, allowing Intellia to advance its flagship ATTR‑CM therapy while its strong financial performance and cash runway provide the resources to support ongoing development and future commercialization efforts.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.